Kristin Centeno, in Adamstown, MD - Physical Medicine & Rehabilitation

Kristin Centeno, is a Physical Medicine & Rehabilitation physician based in Adamstown, Maryland. Kristin Centeno is licensed to practice in Maryland (license number A4606) and her current practice location is 3200 Baker Cir, Adamstown, Maryland. She can be reached at her office (for appointments etc.) via phone at (240) 308-4897.

NPI number for Kristin Centeno is 1235601287 and her current mailing address is 2433 Lakeside Dr, Frederick, Maryland. She does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1235601287.

Contact Information

	Kristin Centeno,
	3200 Baker Cir, Adamstown, MD 21710-9653
	(240) 308-4897
	Not Available

Physician's Profile

Full Name	Kristin Centeno
Gender	Female
Speciality	Physical Medicine & Rehabilitation
Location	3200 Baker Cir, Adamstown, Maryland
Accepts Medicare Assignments	Does not participate in Medicare Program. She may not accept medicare assignment.

NPI Data:

NPI Number: 1235601287
Provider Enumeration Date: 12/31/2018
Last Update Date: 12/31/2018

Medical Identifiers

Medical identifiers for Kristin Centeno such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1235601287	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208100000X	Physical Medicine & Rehabilitation	A4606 (Maryland)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Kristin Centeno is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Kristin Centeno, 2433 Lakeside Dr, Frederick, MD 21702-3157 Ph: (240) 308-4897	Kristin Centeno, 3200 Baker Cir, Adamstown, MD 21710-9653 Ph: (240) 308-4897

News Archive

Repro-Med Systems receives FDA marketing approval for new subcutaneous needle sets

Repro-Med Systems, Inc., announced today that it has received approval from the Food and Drug Administration to begin U.S. marketing of its new Subcutaneous Needle Sets which the company is promoting as the HIgh Flo RMS Subcutaneous Needle Sets.

AGA guidelines recommend RFA for removal of precancerous cells in patients with Barrett's esophagus

New guidelines issued by the American Gastroenterological Association (AGA) support the use of radiofrequency ablation (RFA) to remove precancerous cells in patients with Barrett's esophagus, a condition most commonly caused by chronic acid reflux, or GERD. Barrett's esophagus is the leading cause of esophageal cancer and affects an estimated two million Americans.

New clinical study to examine novel dietary approach for TNBC

A new clinical trial for women with clinically aggressive triple-negative breast cancer (TNBC) will test a novel theory: Will a diet low in an essential nutrient make TNBC cells more vulnerable to cell killing by a new cancer drug?

Regular use of laxatives may flatten rigidity found in Parkinson's disease

In a recent retrospective analysis, investigators discovered that the year-on-year increase in rigidity found in Parkinson's disease flattened off with the regular use of laxatives to manage constipation.

FDA grants 12-year exclusivity to RUCONEST (C1 esterase inhibitor [recombinant])

Salix Pharmaceuticals and Pharming Group NV announced today that the U.S. Food and Drug Administration has granted 12 years of exclusivity to RUCONEST (C1 esterase inhibitor [recombinant]) 50 IU/kg.

Kristin Centeno, - Physical Medicine & Rehabilitation in Adamstown, MD